CoChat
Sign Up
Cited by 20Genetic Neurodegenerative DiseasesVirus-based gene therapy researchLysosomal Storage Disorders Research

Moving toward a gene therapy for Huntington’s disease

Open access
Glorioso, J C, Cohen, J B, Carlisle, D L, Munoz-Sanjuan, I, Friedlander, R M·2015·Gene Therapy
DOI 10.1038/gt.2015.102
Open this paper in CoChat — free accountOpen PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/gt.2015.102

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 40

  1. Paulsen JS. Early detection of Huntington disease. Future Neurol 2010; 5: 85-104.
  2. Garriga-Canut M, Agustín-Pavón C, Herrmann F, Sánchez A, Dierssen M, Fillat C et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 2012; 109: E3136-E3145.
  3. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neu- ropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577.
  4. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-384.
  5. Cisbani G, Cicchetti F. An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis 2012; 3: e382.
  6. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988; 85: 5733-5737.
  7. Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann NY Acad Sci 2008; 1147: 196-205.
  8. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008; 27: 2803-2820.
  9. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential ther- apeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-981.
  10. Bithell A, Johnson R, Buckley NJ. Transcriptional dysregulation of coding and non- coding genes in cellular models of Huntington's disease. Biochem Soc Trans 2009; 37: 1270-1275.
  11. Yano H, Baranov SV, Baranova OV, Kim J, Pan Y, Yablonska S et al. Inhibition of mitochondrial protein import by mutant huntingtin. Nat Neurosci 2014; 17: 822-831.
  12. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C et al. Wild-type hun- tingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000; 20: 3705-3713.
  13. Kumar P, Kalonia H, Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol Rep 2010; 62: 1-14.
  14. Ramaswamy S, McBride JL, Kordower JH. Animal models of Huntington's disease. ILAR J 2007; 48: 356-373.
  15. Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 1999; 10: 2987-2997.
  16. Huang B, Schiefer J, Sass C, Landwehrmeyer GB, Kosinski CM, Kochanek S. High- capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther 2007; 18: 303-311.
  17. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 2004; 9: 682-688.
  18. McBride JL, During MJ, Wuu J, Chen EY, Leurgans SE, Kordower JH. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol 2003; 181: 213-223.
  19. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289: 1826-1832.
  20. Denovan-Wright EM, Attis M, Rodriguez-Lebron E, Mandel RJ. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice. J Neurosci Res 2008; 86: 1748-1757.
  21. Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, Zhou L, Herzog CD et al. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis 2009; 34: 40-50.
  22. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008; 105: 5868-5873.
  23. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 5820-5825.
  24. Popovic N, Maingay M, Kirik D, Brundin P. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuro- pathological changes. Exp Neurol 2005; 193: 65-74.
  25. van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther 2008; 19: 710-719.
  26. Zhang Y, Engelman J, Friedlander RM. Allele-specific silencing of mutant Hun- tington's disease gene. J Neurochem 2009; 108: 82-90.
  27. Lombardi MS, Jaspers L, Spronkmans C, Gellera C, Taroni F, Di Maria E et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 2009; 217: 312-319.
  28. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009; 19: 774-778.
  29. Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP et al. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol Dis 2005; 19: 47-56.
  30. Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA 2004; 101: 17616-17621.
  31. Salegio E, Samaranch L, Kells AP, Mittermeyer G, Sebastian WS, Zhou S et al. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther 2013; 20: 348-352.
  32. San Sebastian W, Samaranch L, Heller G, Kells AP, Bringas J, Pivirotto P et al. Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther 2013; 20: 1178-1183.
  33. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci USA 2009; 106: 2407-2411.
  34. Cairns TM, Huang ZY, Gallagher JR, Lin Y, Lou H, Whitbeck JC et al. Patient-specific neutralizing antibody responses to herpes simple virus are attributed to epitopes on gD, gB or both and can be type specific. J Virol. 2015; 89: 9213-9231.
  35. Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clin- ical trial in Parkinson's disease. Mol Ther 2011; 19: 1048-1057.
  36. Miyagawa Y, Marino P, Verlengia G, Uchida H, Goins WF, Yokota S et al. Herpes simplex viral vector design for efficient transduction of non-neuronal cells with- out cytotoxicity. Proc Natl Acad Sci USA 2015; 112: E1632-E1641.
  37. Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol Ther 2014; 23: 99-107.
  38. Fanara P, Wong PY, Husted KH, Liu VM, Kohlstaedt LA, Riiff T et al. Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegen- eration. J Clin Invest 2012; 122: 3159-3169.
  39. Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Dar Santos R et al. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Mov Disord 2015; 30: 393-401.
  40. Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P et al. Meta- bolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 2001; 42: 1591-1595.

Cited by

Sorted by citations

Authors
Glorioso, J. C., Cohen, J. B., Carlisle, D. L., Munoz-Sanjuan, I., & Friedlander, R. M.
Affiliations
University of Pittsburgh (US)
ORCID
Venue
Gene Therapy
Publisher
Springer Science and Business Media LLC
Published
2015-12
Volume
22
Issue
12
Pages
931-933
ISSN
  • 0969-7128 (ISSN-L)
  • 1476-5462
DOI
10.1038/gt.2015.102
OpenAlex
W2184688258
Cited by
20
References
2
Citations by year
2024: 3 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 1
FWCI
1.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
Keywords
Huntington's disease, neurodegenerative diseases, vector delivery, targeted gene delivery, neuronal loss, glial cells, late-onset disease, Parkinson's disease, early diagnosis
MeSH terms
Animals, Disease Models, Animal, Humans, Huntington Disease, Peptides, Genetic Therapy, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review